Dapagliflozin ((2S) -1,2-propanediol, hydrate)

Dapagliflozin ((2S) -1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin ((2S) -1,2-propanediol, hydrate), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine[1]. Dapagliflozin ((2S) -1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury[2].

Product Specifications

CAS Number

[960404-48-2]

Product Name Alternative

BMS-512148 (2S) -1,2-propanediol, hydrate

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

SGLT

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Dapagliflozin-_2S_-1,2-propanediol,-hydrate.html

Purity

99.99

Solubility

DMSO : ≥ 100 mg/mL|H2O : 2.38 mg/mL (ultrasonic)

Smiles

O[C@H]1[C@H](C2=CC(CC3=CC=C(OCC)C=C3)=C(Cl)C=C2)O[C@H](CO)[C@@H](O)[C@@H]1O.C[C@H](O)CO.O

Molecular Formula

C24H35ClO9

Molecular Weight

502.98

Precautions

H302, H315, H319, H335

References & Citations

[1]Pedersen MG, et al. Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells. Sci Rep. 2016 Aug 18;6:31214.|[2]Chang YK, et al. Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury. PLoS One. 2016 Jul 8;11 (7) :e0158810.|[3]Chiba Y, et al. Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice. PLoS One. 2016 Mar 10;11 (3) :e0150756.